Core Scientific Pushes AI Data Center Expansion Amid Rising Build Costs

What happened

At the TD Cowen TMT Conference, CEO Adam Sullivan said Core Scientific is focusing on expanding five new data center sites and diversifying its customer base to win long-term AI infrastructure contracts. The statement aligns with the company's pivot from bitcoin mining to AI colocation, but the master report highlights that the buildout is capital-intensive and carries significant execution risk. Core Scientific has ~350 MW energized toward a 590 MW target for CoreWeave, but customer concentration remains extreme, with CoreWeave accounting for 100% of colocation revenue. The company also carries a material weakness in internal controls over conversion accounting and a $500 million term loan maturing in March 2027. While management talks up expansion, the financial reality—declining cash, heavy capex commitments, and a strained balance sheet—keeps the risk-reward unattractive at current levels.

Implication

The news reinforces management's AI pivot narrative but does not address the fundamental risk of capital impairment. With $989.8 million in capex commitments, a maturing term loan, and a material weakness in controls tied to the core conversion process, the stock offers no margin of safety. Even if the five new sites materialize, they will only add to the funding pressure before delivering incremental revenue. The bull case depends on flawless execution and continued customer funding, both of which are fragile. Until quarterly filings confirm energized-to-billable conversion progress and a term-out plan for the 2027 debt, the expected payoff from buying today is dominated by downside risks.

Thesis delta

The article does not change the investment thesis; it merely reiterates management's existing expansion ambitions. The core risks—credit maturity, customer concentration, and accounting control failures—remain unresolved, and the new sites likely increase near-term funding needs. Therefore, the 'WAIT' rating and attractive entry of $14 are reaffirmed, with no compelling reason to adjust the stance.